Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Abstract Background Widely established targeted therapies directed at triple negative breast cancer (TNBC) are missing. Classical chemotherapy remains the systemic treatment option. Cisplatin has been tested in TNBC but bears the disadvantage of resistance development. The purpose of this study was...

Full description

Bibliographic Details
Main Authors: Katharina Gohr, Alexandra Hamacher, Laura H. Engelke, Matthias U. Kassack
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Cancer
Subjects:
Triple negative breast cancer
HCC38
MDA-MB231
EGFR
IGF1R
NVP-AEW541
Online Access:http://link.springer.com/article/10.1186/s12885-017-3695-5

Internet

http://link.springer.com/article/10.1186/s12885-017-3695-5

Similar Items